Related Experiment Videos
RET oncogene activation in papillary thyroid carcinoma
1Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA. tallini@yale.edu
Advances in Anatomic Pathology
|November 15, 2001
Summary
RET proto-oncogene rearrangements, known as RET/PTC, are common in papillary thyroid cancer, especially after radiation exposure. These DNA alterations are linked to tumor development and have significant clinical implications.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The RET proto-oncogene encodes a tyrosine kinase receptor involved in cell signaling.
- RET rearrangements (RET/PTC) are associated with papillary thyroid carcinoma (PTC) and Multiple Endocrine Neoplasia type 2 (MEN2).
Purpose of the Study:
- To review the role of RET/PTC rearrangements in papillary thyroid carcinoma.
- To discuss the mechanisms and clinical implications of RET/PTC activation.
Main Methods:
- Review of existing literature on RET proto-oncogene and RET/PTC rearrangements.
- Analysis of the frequency and types of RET/PTC in radiation-induced and sporadic PTC.
Main Results:
- Over 15 types of RET/PTC rearrangements exist, commonly involving RET/PTC1 and RET/PTC3.
- RET/PTC rearrangements are frequent in radiation-associated PTC and found in up to half of sporadic PTC in North America.
- These rearrangements result from DNA damage, fusing the RET tyrosine kinase domain with other genes.
Conclusions:
- RET/PTC rearrangements are a key factor in papillary thyroid carcinoma development.
- Understanding these genetic alterations is crucial for clinical and pathological management of thyroid cancer.